Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
AssigneeBone Care International, Inc.
InventorsCharles W. Bishop, Joyce C. Knutson, Charles R. Valliere
Life of this patent
Estimating the term…
Abstract
Method of treating prostatic conditions such as prostate cancer and hyperplasia by administering 1.alpha.-hydroxyprevitamin D or activated vitamin D or a combination thereof in a sustained release form or a delayed and sustained release formulation. Both the sustained release form and the delayed, sustained release form deliver increased active vitamin D blood levels without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms, to provide the beneficial effect to the diseased prostate tissue.
Claims24
A method of inhibiting the hyperproliferative cellular activity of human prostatic cancer or hyperplasia, comprising administering to a subject suffering therefrom and having a stomach and a small intestine, an effective amount of an oral medicament including a vitamin D compound which is 1.alpha.-hydroxyprevitamin D or an active vitamin D contained in a matrix, said matrix having means for releasably binding and controllably releasing said active vitamin D over a sustained period of time.
A method for the treatment of prostatic diseases characterized by abnormal cell differentiation or cell proliferation, comprising administering to a male human in need of such treatment an effective proliferation-inhibiting amount of an oral medicament which is 1.alpha.-hydroxyprevitamin D compound or a vitamin D compound contained in a matrix, said vitamin D compound being an active vitamin D or a 1.alpha.-hydroxyprevitamin D, said matrix having means for releasably binding and controllably releasing said vitamin D compound over a sustained period of time.
A method of treating human prostate cancer, comprising administering to a male subject who has prostate cancer an effective amount of a composition having a first anticancer agent which is 1.alpha.-hydroxyprevitamin D, a sustained release form of an active vitamin D compound or a delayed, sustained release form of an active vitamin D compound.
A pharmaceutical composition, comprising
- (a) a first anticancer agent which is a vitamin D compound selected from the group consisting of a 1.alpha.-hydroxyprevitamin D, an SR active vitamin D, DSR active vitamin D, and combinations thereof;
- and
- (b) an agent selected from the group consisting of (i) a second anticancer agent, (ii) a bone agent, (iii) an androgen control agent, (iv) a 5.alpha.-reductase inhibitor and combinations thereof.
A method of treating a human to alleviate the hyperproliferative cellular activity of prostatic cancer or hyperplasia, comprising administering to a male human in need thereof a therapeutically effective amount of 1.alpha.-hydroxyprevitamin D or active vitamin D in a formulation which is a sustained release form or a delayed, sustained release form, to decrease or stabilize prostate cancer or hyperplasia cellular activity and to effect a decreased risk of hypercalcemia.
Dependencies are inferred from the claim text.